From Investing.com: 2024-11-16 05:00:00

1) RBC Capital Markets addresses top investor questions regarding the biotechnology sector, including concerns about Trump administration’s impact on FDA and Vertex Pharmaceuticals’ phase II trial for suzetrigine.
2) Regeneron faces queries on EyleaHD adoption and Gilead scrutinized for lenacapavir program in PrEP, while Edgewise Therapeutics and Legend Biotech are monitored for upcoming data releases.
3) Investor spotlight on Amgen’s MariTide and Exelixis’ acquisition targets, along with Ideaya Biosciences’ IDE397 profile and Jazz Pharmaceuticals’ zanidatamab commercial potential in HER2+ cancers.



Read more at Investing.com: RBC’s top 10 questions and answers on biotech stocks By Investing.com